Here is why: Pfizer wants badly replacement to their Lyrica as Lyrica's patent expires in 2018. They are worried about loosing market share and Z160 will fit very nicely. IF the new formulation that Zalicus is working on proves to be successful, we will see stock opening $2+ minimum or possibly even higher.
Hey Kris, do you work at Pfizer? I own some PFE shares and have seen no mention of PFE looking at this POS ZLCS. ZLCS has been nothing buy hype since I bought in a couple years ago. I missed the $3.32 pop and IMO, I doubt it will ever get close to that price again. If it would only pop to a buck I would be gone quickly.